Search

Home > The Bio Report > Repurposing a Drug for Parasitic Infections as a Targeted GI Therapy
Podcast: The Bio Report
Episode:

Repurposing a Drug for Parasitic Infections as a Targeted GI Therapy
Category: Business
Duration: 00:20:46
Publish Date: 2022-01-13 09:00:18
Description: When AzurRX BioPharma merged with First Wave Bio last year, it became a public company and renamed itself First Wave BioPharma. The company is developing targeted, non-systemic therapies for gastrointestinal diseases with its lead candidate niclosamide, an approved therapy to treat pinworms that it believes has anti-viral and anti-inflammatory properties. The company is developing niclosamide in six GI-indications including COVID-19 related GI disease, Immune Checkpoint Inhibitor-associated colitis and diarrhea in advanced oncology patients, ulcerative proctitis/ proctosigmoiditis, ulcerative colitis, and Crohn’s disease. We spoke to James Sapirstein, CEO of First Wave BioPharma, about the merger, niclosamide, and its potential to treat a range of gastrointestinal disorders.
Total Play: 0

Some more Podcasts by Levine Media Group

600+ Episodes
The Bio Repo ..